effects.levalbuterolMonitor Closely (1)meprobamate increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levorphanolMonitor Closely (1)levorphanol and meprobamate both increase sedation. Use Caution/Monitor.lisdexamfetamineMonitor Closely (1)meprobamate increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lofepramineMonitor Closely (1)lofepramine and meprobamate both increase sedation. Use Caution/Monitor.lofexidineMonitor Closely (1)lofexidine and meprobamate both increase sedation. Use Caution/Monitor.loprazolamMonitor Closely (1)loprazolam and meprobamate both increase sedation. Use Caution/Monitor.lorazepamMonitor Closely (1)lorazepam and meprobamate both increase sedation. Use Caution/Monitor.lormetazepamMonitor Closely (1)lormetazepam and meprobamate both increase sedation. Use Caution/Monitor.loxapineMonitor Closely (1)loxapine and meprobamate both increase sedation. Use Caution/Monitor.loxapine inhaledMonitor Closely (1)loxapine inhaled and meprobamate both increase sedation. Use Caution/Monitor.lurasidoneMonitor Closely (1)lurasidone, meprobamate. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilineMonitor Closely (1)maprotiline and meprobamate both increase sedation. Use Caution/Monitor.marijuanaMonitor Closely (1)marijuana and meprobamate both increase sedation. Use Caution/Monitor.melatoninMonitor Closely (1)melatonin and meprobamate both increase sedation. Use Caution/Monitor.meperidineMonitor Closely (1)meperidine and meprobamate both increase sedation. Use Caution/Monitor.metaproterenolMonitor Closely (1)meprobamate increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxaloneMonitor Closely (1)metaxalone and meprobamate both increase sedation. Use Caution/Monitor.methadoneMonitor Closely (1)methadone and meprobamate both increase sedation. Use Caution/Monitor.methamphetamineMonitor Closely (1)meprobamate increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methocarbamolMonitor Closely (1)methocarbamol and meprobamate both increase sedation. Use Caution/Monitor.methylenedioxymethamphetamineMonitor Closely (1)meprobamate increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metoclopramide intranasalSerious - Use Alternative (1)meprobamate, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.midazolamMonitor Closely (1)midazolam and meprobamate both increase sedation. Use Caution/Monitor.midodrineMonitor Closely (1)meprobamate increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mirtazapineMonitor Closely (1)meprobamate and mirtazapine both increase sedation. Use Caution/Monitor.modafinilMonitor Closely (1)meprobamate increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.morphineMonitor Closely (1)morphine and meprobamate both increase sedation. Use Caution/Monitor.motherwortMonitor Closely (1)meprobamate and motherwort both increase sedation. Use Caution/Monitor.moxonidineMonitor Closely (1)meprobamate and moxonidine both increase sedation. Use Caution/Monitor.nabiloneMonitor Closely (1)meprobamate and nabilone both increase sedation. Use Caution/Monitor.nalbuphineMonitor Closely (1)nalbuphine and meprobamate both increase sedation. Use Caution/Monitor.norepinephrineMonitor Closely (1)meprobamate increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.nortriptylineMonitor Closely (1)nortriptyline and meprobamate both increase sedation. Use Caution/Monitor.olanzapineMonitor Closely (1)olanzapine and meprobamate both increase sedation. Use Caution/Monitor.oliceridineMonitor Closely (1)oliceridine, meprobamate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.olopatadine intranasalSerious - Use Alternative (1)meprobamate and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. opium tinctureMonitor Closely (1)opium tincture and meprobamate both increase sedation. Use Caution/Monitor.orphenadrineMonitor Closely (1)orphenadrine and meprobamate both increase sedation. Use Caution/Monitor.oxazepamMonitor Closely (1)oxazepam and meprobamate both increase sedation. Use Caution/Monitor.oxycodoneMonitor Closely (1)oxycodone and meprobamate both increase sedation. Use Caution/Monitor.oxymorphoneMonitor Closely (1)oxymorphone and meprobamate both increase sedation. Use Caution/Monitor.paliperidoneMonitor Closely (1)paliperidone and meprobamate both increase sedation. Use Caution/Monitor.papaveretumMonitor Closely (1)papaveretum and meprobamate both increase sedation. Use Caution/Monitor.papaverineMonitor Closely (1)meprobamate and papaverine both increase sedation. Use Caution/Monitor.pentazocineMonitor Closely (1)pentazocine and meprobamate both increase sedation. Use Caution/Monitor.pentobarbitalMonitor Closely (1)pentobarbital and meprobamate both increase sedation. Use Caution/Monitor.perphenazineMonitor Closely (1)perphenazine and meprobamate both increase sedation. Use Caution/Monitor.phendimetrazineMonitor Closely (1)meprobamate increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenobarbitalMonitor Closely (1)phenobarbital and meprobamate both increase sedation. Use Caution/Monitor.phentermineMonitor Closely (1)meprobamate increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrineMonitor Closely (1)meprobamate increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.phenylephrine POMonitor Closely (1)meprobamate increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .pholcodineMonitor Closely (1)meprobamate and pholcodine both increase sedation. Use Caution/Monitor.pimozideMonitor Closely (1)pimozide and meprobamate both increase sedation. Use Caution/Monitor.pirbuterolMonitor Closely (1)meprobamate increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.pregabalinMonitor Closely (1)pregabalin, meprobamate. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.primidoneMonitor Closely (1)primidone and meprobamate both increase sedation. Use Caution/Monitor.prochlorperazineMonitor Closely (1)prochlorperazine and meprobamate both increase sedation. Use Caution/Monitor.promethazineMonitor Closely (1)promethazine and meprobamate both increase sedation. Use Caution/Monitor.propofolMonitor Closely (1)propofol and meprobamate both increase sedation. Use Caution/Monitor.propylhexedrineMonitor Closely (1)meprobamate increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.protriptylineMonitor Closely (1)protriptyline and meprobamate both increase sedation. Use Caution/Monitor.quazepamMonitor Closely (1)quazepam and meprobamate both increase sedation. Use Caution/Monitor.quetiapineMonitor Closely (1)quetiapine and meprobamate both increase sedation. Use Caution/Monitor.ramelteonMonitor Closely (1)meprobamate and ramelteon both increase sedation. Use Caution/Monitor.risperidoneMonitor Closely (1)risperidone and meprobamate both increase sedation. Use Caution/Monitor.sageMinor (1)meprobamate and sage both increase sedation. Minor/Significance Unknown.salmeterolMonitor Closely (1)meprobamate increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.scullcapMonitor Closely (1)meprobamate and scullcap both increase sedation. Use Caution/Monitor.secobarbitalMonitor Closely (1)secobarbital and meprobamate both increase sedation. Use Caution/Monitor.sevofluraneMonitor Closely (1)sevoflurane and meprobamate both increase sedation. Use Caution/Monitor.shepherd's purseMonitor Closely (1)meprobamate and shepherd's purse both increase sedation. Use Caution/Monitor.sodium oxybateSerious - Use Alternative (1)meprobamate, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.stiripentolMonitor Closely (1)stiripentol, meprobamate. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.sufentanilMonitor Closely (1)sufentanil and meprobamate both increase sedation. Use Caution/Monitor.sufentanil SLSerious - Use Alternative (1)sufentanil SL, meprobamate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may result in hypotension, profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tapentadolMonitor Closely (1)tapentadol and meprobamate both increase sedation. Use Caution/Monitor.temazepamMonitor Closely (1)temazepam and meprobamate both increase sedation. Use Caution/Monitor.terbutalineMonitor Closely (1)meprobamate increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.thioridazineMonitor Closely (1)thioridazine and meprobamate both increase sedation. Use Caution/Monitor.thiothixeneMonitor Closely (1)thiothixene and meprobamate both increase sedation. Use Caution/Monitor.topiramateMonitor Closely (1)meprobamate and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadolMonitor Closely (1)tramadol and meprobamate both increase sedation. Use Caution/Monitor.trazodoneMonitor Closely (1)trazodone and meprobamate both increase sedation. Use Caution/Monitor.triazolamMonitor Closely (1)triazolam and meprobamate both increase sedation. Use Caution/Monitor.triclofosMonitor Closely (1)triclofos and meprobamate both increase sedation. Use Caution/Monitor.trifluoperazineMonitor Closely (1)trifluoperazine and meprobamate both increase sedation. Use Caution/Monitor.trimipramineMonitor Closely (1)trimipramine and meprobamate both increase sedation. Use Caution/Monitor.triprolidineMonitor Closely (1)triprolidine and meprobamate both increase sedation. Use Caution/Monitor.xylometazolineMonitor Closely (1)meprobamate increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.yohimbineMonitor Closely (1)meprobamate increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ziconotideMonitor Closely (1)meprobamate and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneMonitor Closely (1)ziprasidone and meprobamate both increase sedation. Use Caution/Monitor. Frequency Not Defined Common Abnormal ECG, palpitations, tachyarrhythmia Asthenia, ataxia, dizziness, EEG abnormality, euphoria, fast, excitement, paradoxical, headache, paresthesia, slurred speech, somnolence, vertigo Hives, maculopapular eruption, erythematous Diarrhea, nausea, vomiting Disorder of accommodation (ocular) Serious Cardiac dysrhythmia, hypotension crisis, syncope Bullous dermatosis (rare), Stevens-Johnson syndrome (rare) Agranulocytosis, aplastic anemia, leukopenia Anaphylaxis (rare) Contraindications Hypersensitivity or idiosyncratic reactions to drug or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal Acute intermittent porphyria Cautions The lowest effective dose should be administered, particularly to elderly and/or debilitated patients, in order to preclude oversedation The possibility of suicide attempts should be considered and the least amount of drug feasible dispensed at any one time Meprobamate is metabolized in the liver and excreted by the kidney; to avoid excess accumulation, exercise caution in administration to patients with compromised liver or kidney function Meprobamate occasionally may precipitate seizures in epileptic patients Patients should be warned that therapy may impair mental and/or physical abilities required for performance of potentially hazardous tasks such as driving or operating machinery Drug dependence Physical dependence, psychological dependence, and abuse reported; when chronic intoxication from prolonged use occurs, usually involves ingestion of greater than recommended doses and manifested by ataxia, slurred speech, and vertigo; careful supervision of dose and amounts prescribed advised, as well as avoidance of prolonged administration, especially for alcoholics and other patients with a known propensity for taking excessive quantities of drugs Sudden withdrawal of drug after prolonged and excessive use may precipitate recurrence of pre-existing symptoms such as anxiety, anorexia, insomnia, or withdrawal reactions such as vomiting, ataxia, tremors, muscle twitching, confusional states, hallucinosis, and rarely, convulsive seizures Such seizures are more likely to occur in persons with central nervous system damage or pre-existent or latent convulsive disorders; onset of withdrawal symptoms occurs usually within 12-48 hr after discontinuation of meprobamate; symptoms usually cease within next 12-48 hr When excessive dosage has continued for weeks or months, dosage should be reduced gradually over period of one or two weeks rather than abruptly stopped; alternatively, a long-acting barbiturate may be substituted, then gradually withdrawn Drug interaction overview Since effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive, exercise appropriate caution with patients who take more than one of these agents simultaneously Pregnancy An increased risk of congenital malformations associated with use of minor tranquilizers (meprobamate, chlordiazepoxide, and diazepam) during first trimester of pregnancy suggested in several studies Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided; the possibility that a woman of childbearing potential may be pregnant at time of institution of therapy should be considered Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physician about the desirability of discontinuing the drug Meprobamate passes the placental barrier; it is present in umbilical cord blood at or near maternal plasma levels Lactation Present in breast milk of lactating mothers at concentrations two to four times that of maternal plasma; when use of meprobamate is contemplated in breastfeeding patients, the drug's higher concentration in breast milk as compared to maternal plasma should be consideredPregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available. Mechanism of Action Carbamate derivative; inhibitory effects in thalamus, limbic system; may inhibit multineural spinal reflexes Mild sedative, anticonvulsant, muscular relaxant effects Pharmacokinetics Absorption: well-absorbed from GI tract Half-Life: 6-16 hr Onset: <1 hr Peak plasma time: 1-3hr Peak plasma concentration: 5-30 mcg/mL (400 mg dose) Protein Bound: 20% Metabolism: Liver Metabolites: Inactive Excretion: Urine (8-20%); feces (10%) BRAND FORM. UNIT PRICE PILL IMAGE meprobamate oral- 400 mg tabletmeprobamate oral- 200 mg tabletmeprobamate oral- 400 mg tabletmeprobamate oral- 200 mg tabletCopyright © 2010 First DataBank, Inc.Print Patient Educationmeprobamate oral MEPROBAMATE - ORAL (meh-PRO-buh-mate) COMMON BRAND NAME(S): Equanil USES: This medication is used short-term to treat symptoms of anxiety and nervousness. It acts on certain centers of the brain to help calm your nervous system. HOW TO USE: Take